Determining the cause of dyspnoea: Linguistic and biological descriptors

Chronic Respiratory Disease

Volumn 3, Issue 3, 2006, Pages 117-122

  Ambrosino, Nicolino ^a   Serradori, M ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NATRIURETIC FACTOR;

CARDIOPULMONARY INSUFFICIENCY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DYSPNEA; ENDOCRINE FUNCTION; HEART DISEASE; HEART FAILURE; PRIORITY JOURNAL; REVIEW;

DIAGNOSIS, DIFFERENTIAL; DYSPNEA; HEART; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROTEIN PRECURSORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 33747111750     PISSN: 14799723     EISSN: 14799731     Source Type: Journal    
DOI: 10.1191/1479972306cd110ra     Document Type: Review

References (63)

1. Comroe JH. Some theories of the mechanism of dyspnea. In Howell JB, Campbell EJM eds. Breathlessness. Blackwell Scientific Publications Inc, 1966: 1-7.
2. American Thoracic Society. Dyspnea. Mechanisms, assessment and management: A consensus statement. Am J Respir Crit Care Med 1999; 159: 321-40.
3. Scano O, Ambrosino N. Pathophysiology of dyspnea. Lung 2002; 180: 131-48.
4. Voduc N, Webb K, O'Donnell D. Physiological basis of dyspnea. In Dannex CF, Ambrosino N, Goldstein RS eds. Pulmonary rehabilitation: efficacy and scientific basis. Arnold Pub, 2005: 124-35.
5. Simon PM, Schwartzstein RM, Woodrow Weiss J, Fencl V, Teghtsoonian M, Weimberger SE. Distinguishable types of dyspnoea in patients with shortness of breath. Am Rev Respir Dis 1990; 142: 1009-14.
6. Elliot MW, Adams L, Cockcroft A, Macrae KD, Murphy K, Guz A. The language of breathlessness: use of verbal descriptors by patients with cardiorespiratory disease. Am Rev Respie Dis 1991; 144: 826-32.
7. Banzett RB, Lansing RW, Brown R et al. 'Air hunger' arising from increased PCO2 persists after complete neuromuscular block in humans. Respir Physiol 1990; 81: 1-17.
8. Banzett RB, Lansing RW, Reid MB, Adams L, Brown R. 'Air hunger' arising from increased PCO2 in mechanically ventilated quadriplegics. Respir Physiol 1989; 76: 53-68.
9. Mahler DA, Harver A, Lentine T, Scott JA, Beck K, Schwartzstein RM. Descriptors of breathlessness in cardiorespiratory diseases. Am J Respir Crit Care Med 1996; 154: 1357-63.
10. Killian KJ, Watson R, Otis J, St Amand TA, O'Byrne PM. Symptom perception during acute bronchoconstriction. Am J Respir Crit Care Med 2000; 162: 490-96.
11. Hardie GE, Jonson S, Gold WM, Carrieri-Kolhman V, Boushey H. Ethnic differences: word descriptors used by African American and white asthma patients during induced bronchocostriction. Chest 2000; 117: 928-29.
12. Foglio K, Carone M, Pagani M, Bianchi L, Jones PW, Ambrosino N. Physiological and symptom determinants of exercise performance in patients with chronic airway obstruction (CAO). Respir Med 2000; 94: 256-63.
13. Rossi A, Polese G, Brandi G, Conti G. Intrinsic positive end-expiratory pressure (PEEPi). Intensive Care Med 1995; 21: 522-36.
14. Pride NB, Macklem PT. Lung mechanics in disease. In Fishman AP ed. Handbook of physiology, Section 3, Vol. III, Part 2: The respiratory system. Am Physiol Soc, 1986; 659-92.
15. Binks AP, Moosavi SH, Banzett RB, Harver A, Mahler DA, Schwartzstein RM. "Tightness" sensation of asthma does not arise from the work of breathing. Am J Respir Crit Care Med 2002; 165: 78-82.
16. Lougheed MD, Lam M, Forkert L, Webb KA. O'Donnell DE. Breathlessness during acute bronchoconstriction in asthma. Am Rev Respir Dis 1993; 148: 452-59.
17. Moy ML, Woodrow Weiss J, Sparrow D, Israel E, Schwartzstein RM. Quality of dyspnoea in bronchoconstriction differs from external resistive loads. Am J Respir Crit Care Med 2000; 162: 451-55.
18. Gorini M, Iandelli I, Misuri G et al. Chest wall hyperinflation during acute bronchoconstriction in asthma. Am J Respir Crit Care Med 1999; 160: 808-16.
19. Moy ML, Latin ML, Harver A, Mahler DA, Schwartzstein RM. Language of dyspnoea in assessment of patients with acute asthma treated with nebulized albuterol. Am J Respir Crit Care Med 1998; 158: 749-53.
20. Scano G, Grazzini M, Stendardi L, Ambrosino N. Dyspnoea and asthma. Monaldi Arch Chest Dis 1998; 53: 672-76.
21. Braek T, Jubran A, Tobin M. Dyspnoea and decreased variability of breathing in patients with restrictive lung disease. Am J Crit Care Med 2002; 165: 1260-64.
22. Lansing RW, Im BS-H, Thwing JI, Legedza ATR, Banzett RB. The perception of respiratory work and effort can be independent of the perception of air hunger. Am J Respir Crit Care Med 2000; 162: 1690-96.
23. Lanini B, Misuri G, Gigliotti F et al. Perception of dyspnoea in patients with neuromuscular disease. Chest 2001; 120: 402-408.
24. Lanini B, Gigliotti F, Coli C et al. Dissociation between respiratory effort and dyspnoea in a subset of patients with stroke. Clin Sci 2002; 103: 467-73.
25. Scano G, Seghieri G, Mancini M et al. Dyspnoea, peripheral airway involvement and respiratory muscle effort in patients with Type I diabetes mellitus under good metabolic control. Clin Sci 1999; 96: 499-506.
26. Clark AL, Sparrow JL, Coates AJS. Muscle fatigue and dyspnoea in chronic heart failure; two sides of the same coin? Eur Heart J 1995; 16: 49-52.
27. Hamilton AL, Killian KJ, Summers E, Jones NL. Muscle strength, symptom intensity, and exercise capacity in patients with cardiorespiratory disorders. Am J Respir Crit Care Med 1995; 152: 2021-31.
28. Killian KJ. The mechanisms of dyspnoea. Eur Respir Rev 2002; 82: 31-33.
29. Schwartzstein RM. The language of dyspnoea. Eur Respir Rev 2002; 12: 82: 28-30.
30. McCullogh PA, Nowak RM, McCord J et al. B-type natriuretic peptide and clinical judgment in emergengy diagnosis of heart failure: analysis from Breathing Not Properly (BNP) multinational study. Circulation 2002; 106: 416-22.
31. Caroci Ade S, Lareau SC. Descriptors of dyspnea by patients with chronic obstructive pulmonary disease versus congestive heart failure. Heart Lung 2004; 33: 102-10.
32. Zile MR, Gaasch WH, Carroll JD et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation 2001; 104: 779-82.
33. Mueller C, Scholer A, Laule-Kalian K et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350: 647-54.
34. Nielsen LS, Svanegaard J, Klitgaard NA, Egeblad H. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail 2004; 6: 63-70.
35. Emdin M, Clerico A, Clemenza F et al. Consensus document. Recommendation for clinical use of cardiac natriuretic peptides. It Heart J 2005; 6: 430-46.
36. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and important natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci 1981; 28: 89-94.
37. de Bold AJ, Bruneau BG. Natriuretic peptides. In Fray JC ed. Handbook of physiology, Section 7, Vol. III. Oxford University Press, 2000: 377-409.
38. Richards AM, Lainchbury JG, Nicholls MG, Cameron AV, Yandle TG. Dendroapsis natriuretic peptide: endogenous or dubious? Lancet 2002; 359: 5-6.
39. Emdin M, Passino C, Prontera C et al. Cardiac natriuretic hormones, neuro.hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Med 2004; 42: 627-36.
40. Belenky A, Smith A, Zhang B et al. The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. Clin Chim Acta 2004; 340: 163-72.
41. Maisel AS, McCord J, Nowak RM et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction: results from the Breathing Not Properly multinational study. J Am Coll Cardiol 2003; 41: 2010-17.
42. Clerico A, Iervasi G, Del Chicca MG et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest 1998; 21: 170-79.
43. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003; 42: 728-35.
44. Omland T, Aakvaag A, Bonarjee WS et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: comparison with plasma atrial natriuretic peptide and n terminal proatrial natriuretic peptide. Circulation 1996; 93: 1963-69.
45. Krishnaswamy P, Lubien E, Clopton P et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001; 111: 274-79.
46. Maisel AS, Koon J, Krishnaswamy P et al. Utility of B-natriuretic peptide as a rapid, point of care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001; 141: 367-74.
47. Harrison A, Morrison LK, Krishnaswamy P et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002; 39: 131-38.
48. Dokatnish H, Zoghbi WA, Lakkis NM et al. Incremental predictive power of B-type natriuretic peptide and tissue Doppler echocardiography in the prognosis of patients with congestive heart failure. J Am Coll Cardiol 2005; 45: 1223-26.
49. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. Br Med J 2005; 330: 625-30.
50. Davis M, Espiner E, Richards G et al. Plasma brain natriuretic peptide in assessment of acute dyspnea. Lancet 1994; 343: 440-44.
51. Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-67.
52. Antonelli Incalzi R, Fuso L, Serra M et al. Exacerbated chronic obstructive pulmonary disease: a frequently unrecognized condition. J Intern Med 2002; 252: 48-55.
53. Mueller C, Laule-Kilian K, Frana B et al. The use of B-type natriuretic peptide in the management of elderly patients with acute dyspnoea. J Intern Med 2005; 258: 77-85.
54. Steg PG, Joubin L, McCord J et al. for the Breathing Not Properly multinational study investigators. B-type natriuretic peptide and echographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. Chest 2005; 128: 21-29.
55. Jefic D, Lee JW, Jefic Di, Saviy-Moore RT, Rosman HS. Utility of B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide in evaluation of respiratory failure in critically ill patients. Chest 2005; 128: 288-95.
56. Goetze JP, Videbaek R, Boesgaard S, Aldershvile J, Rehfeld JF, Carlsen J. Pro-brain natriuretic peptide as marker of cardiovascular or pulmonary causes of dyspnea in patients with terminal parenchymal lung disease. J Heart Lung Transplant 2004; 23: 80-87.
57. Yamamoto K, Burnett JC Jr, Jougasaki M et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28: 988-94.
58. Lang CC, Couties WJ, Struthers AD et al. Elevated levels of brain natriuretic peptide in acute hypxaemic chronic pulmonary disease. Clin Sci (London) 1992; 83: 529-33.
59. Cabanes L, Richaud-Thiriez B, Fulla Y et al. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest 2001; 120: 2047-50.
60. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in atients presenting with dyspnea. J Am Coll Cardiol 2002; 39: 202-209.
61. Ishii J, Nomura M, Ito M et al. Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease. Clin Chim Acta 2000; 301: 19-30.
62. Harrison A, Amundson S. Evaluation and management of the acutely dyspneic patient: the role of biomarkers. Am J Emerg Med 2005; 23: 371-17.
63. Yap LB, Mukerjee D, Timms PM, Ashrafian H, Coghlan JG. Natriuretic peptides, respiratory disease, and the right heart. Chest 2004; 126: 1330-36.